Baba Raises $40M Series A for Medicare Care Coordination

Clinical hiring sits beside AI research in Baba's plans for its new financing. The New York healthcare company announced a $40M Series A on October 20, 2026, led by FirstMark Capital, with CVS Health Ventures, Valtruis and returning investors General Catalyst, Genius Ventures and Ground Up Ventures participating.

Founder and CEO Connor Sweeney is building a business around the work that connects medical care: coordinating appointments, benefits, insurers and the people helping a patient at home. Baba combines human advocates and clinicians with AI support, and plans to expand its clinical teams, research and health-plan relationships while developing value-based arrangements. For healthcare operators, the financing puts an operating question inside the AI investment story: how much responsibility can a care service carry across institutions that each control only part of a patient's experience?

What Baba's Series A Adds

Baba says the Series A brings its total funding to $47M. Its February 2026 seed announcement disclosed more than $6.5M led by General Catalyst, with Genius Ventures, Soma Capital, Ground Up Ventures and Triedge Investments among the participants. The earlier disclosure and the new total are separate company statements; the rounded seed amount should not be used to manufacture an exact capital history.

The company's about page dates its founding to 2025, before its February 2026 public launch. That chronology matters because a public debut can make a young operating company look as though it began on the day it announced funding. Baba had already organized its service around advocates who help families obtain equipment, find specialists, handle insurance appeals and arrange care.

The new round gives the company resources to develop that service and its technology together. The reviewed announcements do not disclose a valuation or investor ownership stakes. They also leave the allocation between clinical capacity, research and commercial expansion open, so the financing describes a direction rather than a published operating budget.

DevCuration's coverage of Vinyl Health's patient-held AI and Sunlight AI's practice support describes adjacent approaches to helping people or providers organize care. Baba's chosen unit of delivery is the advocacy relationship.

The Clinical Team Is Part of the Product

Baba's hiring helps explain the service it wants to sell. In April, the company appointed Alicia Tennenbaum, LCSW, to lead clinical operations. She had served as VP of Case Management at Med-Metrix and, earlier, Executive Director of Care Transitions at Mount Sinai Health System. That background places experience with hospital discharge and post-acute coordination inside Baba's organization.

A discharge plan starts another sequence of work for the patient and family. Medication questions, a specialist referral, transportation and an insurance decision can sit with different organizations. Baba's service description includes helping with those connections, using nurses, social workers and benefits expertise alongside software. Eligibility and insurance coverage still matter; the existence of an advocacy service is not a promise that every patient receives it at no cost.

That makes staffing a substantive product decision. An advocate must understand which person can resolve a problem, what information can be shared and whether the next step actually happened. AI may assist with the workflow, while the clinical organization supplies the judgment and relationships that a family is relying on. As the service reaches more people, the coordination among Baba's own teams becomes part of the delivery problem too.

AI Research Follows the Unfinished Work

The company's BabaBench research examines simulated patient-advocacy tasks that require extended sequences of action. Its design considers whether an agent completes the intended task while respecting consent, authority and information boundaries. Those requirements are unusually relevant to a service that may have to speak with several organizations before a patient can receive care.

A useful answer can arrive early in that process. The remaining work may include obtaining permission, collecting a document, contacting another party and confirming that the requested action occurred. Evaluating the sequence makes the research closer to the coordination job Baba is trying to support. It also makes partial progress a complicated metric: an apparently successful interaction can leave the patient waiting for the part that matters.

BabaBench is a simulation benchmark, not evidence from a clinical outcomes trial. Its relevance to the funding story is the choice of problem: Baba is investing in agents that can navigate a sustained administrative responsibility under constraints. The company still has to determine which steps software should perform, which belong with its human team and how the record of both can remain understandable to the people responsible for care.

The Payment Environment Is Changing the Assignment

Baba said in June that it had been selected for CMS's ACCESS Model across its four initial clinical tracks. Separately, the Centers for Medicare & Medicaid Services describes ACCESS as a ten-year test of outcome-aligned payments for technology-supported chronic care in Original Medicare. The policy context gives Baba's value-based ambitions a specific setting, without establishing the economics of its individual contracts.

CMS ties the model's full payment to measurable health outcomes and requires clinical oversight and coordination with other providers. That creates a different commercial assignment from selling a tool whose usefulness ends when it produces an answer. A care organization has to connect the work it performs to the patient's progress, while maintaining the information and operating discipline needed for accountability.

For Baba, the opportunity rests in making sustained coordination practical for more people. The company-issued funding release reports more than 10,000 patients and families supported and more than 100,000 families waiting, figures that describe reported demand rather than independently established health improvements. As Sweeney develops payer relationships and Tennenbaum's clinical organization grows, the work continues into a family's next referral, the insurer's next request and the appointment that still needs arranging.